 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 April 2002 | Volume 136 Issue 7 | Pages 534-546
In aplastic anemia, hematopoiesis fails: Blood cell counts are extremely low, and the bone marrow appears empty. The pathophysiology of aplastic anemia is now believed to be immune-mediated, with active destruction of blood-forming cells by lymphocytes. The aberrant immune response may be triggered by environmental exposures, such as to chemicals and drugs or viral infections and, perhaps, endogenous antigens generated by genetically altered bone marrow cells. In patients with post-hepatitis aplastic anemia, antibodies to the known hepatitis viruses are absent; the unknown infectious agent may be more common in developing countries, where aplastic anemia occurs more frequently than it does in the West.
The syndrome paroxysmal nocturnal hemoglobinuria (PNH) is intimately related to aplastic anemia because many patients with bone marrow failure have an increased population of abnormal cells. In PNH, an entire class of proteins is not displayed on the cell surface because of an acquired X-chromosome gene mutation. The PNH cells may have a selective advantage in resisting immune attack. In contrast, the disease myelodysplasia can be confused with aplasia and can also evolve from aplastic anemia. The occurrence of cytogenetic abnormalities in patients years after presentation implies that genomic instability is a feature of this immune-mediated disease.
Aplastic anemia can be effectively treated by stem-cell transplantation or immunosuppressive therapy. Transplantation is curative but is best used for younger patients who have histocompatible sibling donors. Antithymocyte globulin and cyclosporine restore hematopoiesis in approximately two thirds of patients. However, recovery of blood cell count is often incomplete, recurrent pancytopenia requires retreatment, and some patients develop late complications (especially myelodysplasia).
Author and Article Information
From the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Acknowledgments: The author thanks Drs. Jaroslaw Maciejewski, John Barrett, Elaine Sloand, and Cynthia Dunbar for their careful reading of the manuscript.
Grant Support: Dr. Young is supported entirely by intramural funds from the National Heart, Lung, and Blood Institute.
Requests for Single Reprints: Neal S. Young, MD, Building 10, Room 7C103, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892-1652. UPDATE
Acquired Aplastic Anemia
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Brodsky How I treat paroxysmal nocturnal hemoglobinuria Blood, June 25, 2009; 113(26): 6522 - 6527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takamatsu, J. L. Espinoza, X. Lu, Z. Qi, K. Okawa, and S. Nakao Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia Stimulate Peripheral Blood Mononuclear Cells to Secrete TNF-{alpha} and IFN-{gamma} J. Immunol., January 1, 2009; 182(1): 703 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dingli, L. Luzzatto, and J. M. Pacheco Neutral evolution in paroxysmal nocturnal hemoglobinuria PNAS, November 25, 2008; 105(47): 18496 - 18500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kenyon and S. L. Gerson The role of DNA damage repair in aging of adult stem cells Nucleic Acids Res., December 26, 2007; (2007) gkm1064v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yu, K.-Y. Yang, X.-Z. Ren, Y. Chen, and X.-H. Liu Amifostine Protects Bone Marrow from Benzene-Induced Hematotoxicity in Mice International Journal of Toxicology, July 1, 2007; 26(4): 315 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gargiulo, S. Lastraioli, G. Cerruti, M. Serra, F. Loiacono, S. Zupo, L. Luzzatto, and R. Notaro Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria Blood, June 1, 2007; 109(11): 5036 - 5042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Meissner, M. Rutkowski, A. L. Harmsen, S. Han, and A. G. Harmsen Type I Interferon Signaling and B Cells Maintain Hemopoiesis during Pneumocystis Infection of the Lung J. Immunol., May 15, 2007; 178(10): 6604 - 6615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, D. P. Sejas, Y. Qiu, D. A. Williams, and Q. Pang Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence J. Cell Sci., May 1, 2007; 120(9): 1572 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Solomou, K. Keyvanfar, and N. S. Young T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia Blood, May 15, 2006; 107(10): 3983 - 3991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sepulveda, U. Brethauer, J. Rojas, and P. Le Fort Oral manifestations of aplastic anemia in children J Am Dent Assoc, April 1, 2006; 137(4): 474 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. W. Marsh Aplastic anemia: what's in the environment? Blood, February 15, 2006; 107(4): 1250 - 1250. [Full Text] [PDF]
|
|
|
|
|
|
S. Issaragrisil, D. W. Kaufman, T. Anderson, K. Chansung, P. E. Leaverton, S. Shapiro, and N. S. Young The epidemiology of aplastic anemia in Thailand Blood, February 15, 2006; 107(4): 1299 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Platanias Interferon-inducible genes and aplastic anemia Blood, January 1, 2006; 107(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen Animal Models for Acquired Bone Marrow Failure Syndromes Clin. Med. Res., May 1, 2005; 3(2): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamaguchi, R. T. Calado, H. Ly, S. Kajigaya, G. M. Baerlocher, S. J. Chanock, P. M. Lansdorp, and N. S. Young Mutations in TERT, the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia N. Engl. J. Med., April 7, 2005; 352(14): 1413 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Maciejewski and A. M. Risitano Aplastic Anemia: Management of Adult Patients Hematology, January 1, 2005; 2005(1): 110 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, K. Lipovsky, F. M. Ellison, R. T. Calado, and N. S. Young Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure Blood, September 15, 2004; 104(6): 1671 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Rose and N. Berliner T-Cell Large Granular Lymphocyte Leukemia and Related Disorders Oncologist, June 1, 2004; 9(3): 247 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Trigg Hematopoietic Stem Cells Pediatrics, April 1, 2004; 113(4/S1): 1051 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takahashi, J. P. McCoy Jr, C. Carvallo, C. Rivera, T. Igarashi, R. Srinivasan, N. S. Young, and R. W. Childs In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation Blood, February 15, 2004; 103(4): 1383 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Bagby, J. M. Lipton, E. M. Sloand, and C. A. Schiffer Marrow Failure Hematology, January 1, 2004; 2004(1): 318 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zeng, G. Chen, S. Kajigaya, O. Nunez, A. Charrow, E. M. Billings, and N. S. Young Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers Blood, January 1, 2004; 103(1): 325 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hirano, M. O. Butler, M. S. von Bergwelt-Baildon, B. Maecker, J. L. Schultze, K. C. O'Connor, P. H. Schur, S. Kojima, E. C. Guinan, and L. M. Nadler Autoantibodies frequently detected in patients with aplastic anemia Blood, December 15, 2003; 102(13): 4567 - 4575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ishiyama, T. Chuhjo, H. Wang, A. Yachie, M. Omine, and S. Nakao Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells Blood, August 15, 2003; 102(4): 1211 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Karadimitris, D. J. Araten, L. Luzzatto, and R. Notaro Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPI- and GPI+ hematopoiesis Blood, July 15, 2003; 102(2): 514 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Steensma, A. Dispenzieri, S. B. Moore, G. Schroeder, and A. Tefferi Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome Blood, March 15, 2003; 101(6): 2156 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rosenfeld, D. Follmann, O. Nunez, and N. S. Young Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia: Association Between Hematologic Response and Long-term Outcome JAMA, March 5, 2003; 289(9): 1130 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frickhofen, H. Heimpel, J. P. Kaltwasser, and H. Schrezenmeier Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia Blood, February 15, 2003; 101(4): 1236 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sperone, G. Gorzegno, A. Berruti, U. Familiari, and L. Dogliotti Reversible Pancytopenia Caused by Oral Letrozole Assumption in a Patient With Recurrent Breast Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3747 - 3748. [Full Text] [PDF]
|
|
